Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aemcolo

(Rifamycin SV Sodium)

CCosmo Technologies Ltd

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Androgenetic Alopecia1 trial

Topical Rifamycin SV After Sapphire FUE: Accelerated Wound Healing and Anticipatory and Preventive Nursing Care

Completed·EElif Asena KANTARCI·Preclinical·NCT07155408·70 enrolled

Regulatory

FDA Approval Timeline[3]

Nov 16, 2018

AEMCOLO

NDA NDA210910

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rifamycin SV Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rifamycin SV Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA210910). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Cosmo Technologies Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: CCosmo Technologies Ltd

Related News